AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Merck says VYTORIN reduces major vascular events in patients with chronic kidney disease.
(From Pharma)
M2PHARMA-November 22, 2010-Merck says VYTORIN reduces major vascular events in patients with chronic kidney disease (C)2010 M2 COMMUNICATIONS http://www.m2.com
22 November 2010 - US Merck & Co Inc (NYSE: MRK) said on Saturday that in a new investigational study of the cholesterol-lowering medicine VYTORIN (ezetimibe/simvastatin), VYTORIN 10/20 mg reduced the incidence of first major vascular events - defined as non-fatal heart attacks or cardiac death, stroke or any revascularisation procedure - by a highly statistically significant 16.1% compared to placebo (p=0.0010).
This was the pre-specified primary endpoint of the study, the company …
-
- Plavix plus aspirin more effective than aspirin alone in preventing major...
-
News wire article from: Chemical Business Newsbase
March 31, 2009
700+ words
-
- VYTORIN (ezetimibe/simvastatin) significantly reduced major vascular events...
-
News wire article from: Chemical Business Newsbase
November 20, 2010
700+ words
-
- Clinical: Journals Watch - Depression and vitamin D deficiency.
-
Magazine article from: GP
August 20, 2010
700+ words
-
- CRP levels do not predict statin therapy success.
-
Magazine article from: GP
February 4, 2011
700+ words
-
- Statins cut cardiovascular events in diabetic patients.
-
Magazine article from: GP
January 18, 2008
700+ words
